歌礼制药－Ｂ:ASC47联合司美格鲁肽治疗肥胖症的美国临床研究完成所有受试者给药

Core Viewpoint - The company has completed a randomized, double-blind, placebo-controlled study assessing the safety, tolerability, and preliminary efficacy of ASC47 in obese subjects without type 2 diabetes, with results expected in Q4 2025 [1] Group 1: Product Overview - ASC47 is a long-acting subcutaneous thyroid hormone receptor β selective small molecule agonist developed by the company, designed to target fat tissue and achieve high drug concentrations in adipose tissue in a dose-dependent manner [1] - In a diet-induced obesity mouse model, ASC47 demonstrated a significant ability to reduce fat compared to semaglutide and tirzepatide, with notable statistical significance [1] Group 2: Clinical Study Insights - The study involved 28 subjects, and ASC47 showed a half-life of up to 40 days in a Phase Ib study of obese subjects [1] - In head-to-head comparisons in a diet-induced obesity mouse model, low-dose ASC47 combined with semaglutide resulted in a 56.7% greater weight reduction compared to semaglutide alone, without muscle loss [1]